Understanding HIV-1 persistence in cytotoxic CD4+ T lymphocytes at the single cell level
在单细胞水平上了解 HIV-1 在细胞毒性 CD4 T 淋巴细胞中的持久性
基本信息
- 批准号:10700380
- 负责人:
- 金额:$ 85.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-11 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAntigen PresentationAntigensBenzoxazolesBioinformaticsCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCarboxylic AcidsCell SurvivalCell secretionCellsClonal ExpansionClone CellsDimensionsFlow CytometryFrequenciesGenesGenetic TranscriptionGoalsGranzymeHIV-1HeterogeneityImmuneIn VitroIndividualInfectionMachine LearningMalignant NeoplasmsMeasurementPersonsPredispositionProliferatingProteinsRNAResearchResolutionSamplingShapesSpecificityT-Cell ProliferationT-Cell ReceptorT-LymphocyteT-Lymphocyte SubsetsTNF geneTestingTimeTumor Necrosis Factor TherapyUp-RegulationValidationViralViral Cytopathogenic EffectViremiaanalysis pipelineanticancer researchantiretroviral therapycancer cellcohortcytokinecytotoxiccytotoxic CD8 T cellsimmune clearancein vivoinhibitormemory CD4 T lymphocytemultiple omicsperforinpolarized cellpreservationpreventprogramsprotein expressionresponsetherapeutic developmenttherapeutic targettooltranscriptometranscriptome sequencing
项目摘要
PROJECT SUMMARY
Despite effective antiretroviral therapy (ART), HIV-1 persists in the latent reservoir lifelong. Although most HIV-
1-infected cells die of viral cytopathic effects or immune clearance, HIV-1-infected cells, even those having active
HIV-1 expression, can survive, persist, and proliferate. We want to examine how HIV-1 establishes infection
during viremia and persists under viral suppression in people living with HIV-1. Understanding the immune cell
subsets, immune programs, and cell markers of HIV-1-infected cells will identify therapeutic targets. The
challenge is the heterogeneity and rarity of HIV-1-infected cells: in ART-treated, virally suppressed individuals,
only 1–100/106 (<0.01%) CD4+ T cells harbor inducible HIV-1. To this end, we profiled CD4+ T cells from the
Sabes cohort during viremia and after viral suppression using single-cell ECCITEseq, which captures single-cell
transcriptome, protein expression, HIV-1 RNA, and T cell receptor sequence (TCR) within the same single cell.
We have established advanced single-cell bioinformatic analysis pipelines and machine learning tools. This
approach enables multi-dimensional, high-resolution, single-cell profiling of immune cell subsets, immune
programs, cell markers, T cell clonal expansion, and HIV-1 RNA+ cells at the same time. Our single-cell
ECCITEseq found that HIV-1 RNA+ cells upregulated cytotoxic CD4+ T cell genes. Using flow cytometric
measurement of HIV-1 p24 protein and granzyme B expression, our RNA-seq based results were validated by
a protein-based orthogonal approach, revealing that HIV-1 persists by hiding in granzyme B+ cytotoxic effector
memory CD4+ T cells. Based on our results from viremic samples, we can examine the rare HIV-1 RNA+ cells
under suppressive ART over time. Using single-cell ECCITEseq, we found that despite suppressive ART, tumor
necrosis factor (TNF) responses persist. Furthermore, antigen and TNF responses drive the proliferation of T
cell clones. In addition, different antigen responses drive distinct T cell polarization and proliferation. Altogether,
we hypothesize that antigen stimulation and TNF responses can shape T cell polarization, cellular susceptibility
to HIV-1 infection, cellular survival, and proliferation of the infected cells, particularly granzyme B cytotoxic CD4+
T cells. Our goal is to understand why HIV-1-infected cytotoxic CD4+ T cells can preferentially survive, proliferate,
and persist, as opposed to other T cell subsets. Achieving this goal will identify immune programs that drive
HIV-1 persistence and identify cell markers for HIV-1-infected cells for more specific therapeutic targeting. Our
approach is to combine cutting-edge single-cell ECCITEseq and orthogonal validations to examine how HIV-1
RNA+ granzyme B+ CTLs survive and persist under viral suppression by profiling cell subsets, immune program,
markers, and proliferation dynamics for the rare HIV-1 RNA+ cells over time during viral suppression in vivo and
in vitro. Overall, we will understand why HIV-1 preferentially persists in cytotoxic CD4+ T cells, identify upstream
immune drivers promoting the survival and proliferation of the HIV-1-infected cytotoxic CD4+ T cells, and guide
the development of therapeutic strategies specific for HIV-1-infected cells.
项目摘要
尽管有有效的抗逆转录病毒治疗(ART),HIV-1仍然存在于潜伏的水库终身。虽然大多数艾滋病毒-
1-感染的细胞死于病毒致细胞病变效应或免疫清除,HIV-1感染的细胞,即使是那些具有活性的细胞,
HIV-1表达,可以存活,持续存在和增殖。我们想研究HIV-1是如何感染的
在HIV-1感染者的病毒血症期间,并在病毒抑制下持续存在。了解免疫细胞
HIV-1感染细胞的亚群、免疫程序和细胞标记将确定治疗靶点。的
挑战是HIV-1感染细胞的异质性和稀有性:在ART治疗的病毒抑制个体中,
仅1-100/106(<0.01%)的CD 4 + T细胞具有可诱导的HIV-1。为此,我们分析了CD 4 + T细胞,
病毒血症期间和病毒抑制后的Sabes队列,使用单细胞ECCITEseq捕获单细胞
转录组、蛋白质表达、HIV-1 RNA和T细胞受体序列(TCR)。
我们已经建立了先进的单细胞生物信息学分析管道和机器学习工具。这
这种方法能够对免疫细胞亚群进行多维、高分辨率、单细胞分析,
程序、细胞标记、T细胞克隆扩增和HIV-1 RNA+细胞。我们的单细胞
ECCITEseq发现HIV-1 RNA+细胞上调细胞毒性CD 4 + T细胞基因。使用流式细胞术
通过测量HIV-1 p24蛋白和颗粒酶B表达,我们基于RNA-seq的结果得到了验证,
一种基于蛋白质的正交方法,揭示了HIV-1通过隐藏在颗粒酶B+细胞毒性效应子中而持续存在。
记忆性CD 4 + T细胞。根据我们从病毒血症样本中获得的结果,我们可以检查罕见的HIV-1 RNA+细胞,
随着时间的推移,使用单细胞ECCITEseq,我们发现,尽管抑制性ART,
坏死因子(TNF)反应持续存在。此外,抗原和TNF应答驱动T细胞增殖,
细胞克隆此外,不同的抗原应答驱动不同的T细胞极化和增殖。总的来说,
我们假设抗原刺激和TNF应答可以影响T细胞极化,细胞易感性,
HIV-1感染、细胞存活和感染细胞增殖,特别是颗粒酶B细胞毒性CD 4 +
T细胞。我们的目标是了解为什么HIV-1感染的细胞毒性CD 4 + T细胞可以优先存活,增殖,
并持续存在,与其他T细胞亚群相反。实现这一目标将确定免疫程序,
HIV-1持久性和识别HIV-1感染细胞的细胞标志物,以实现更特异的治疗靶向。我们
方法是联合收割机结合尖端的单细胞ECCITEseq和正交验证来研究HIV-1如何
RNA+颗粒酶B+ CTL通过分析细胞亚群、免疫程序
标记物,以及在体内病毒抑制期间罕见HIV-1 RNA+细胞随时间的增殖动力学,
体外总的来说,我们将理解为什么HIV-1优先存在于细胞毒性CD 4 + T细胞中,
促进HIV-1感染的细胞毒性CD 4 + T细胞的存活和增殖的免疫驱动因子,并指导
开发针对HIV-1感染细胞的治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ya-Chi Ho其他文献
Ya-Chi Ho的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ya-Chi Ho', 18)}}的其他基金
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir
HIV 储存库持续性和扰动的高清表征
- 批准号:
10469108 - 财政年份:2022
- 资助金额:
$ 85.69万 - 项目类别:
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir
HIV 储存库持续性和扰动的高清表征
- 批准号:
10654759 - 财政年份:2022
- 资助金额:
$ 85.69万 - 项目类别:
M-SCORCH: Methamphetamine use disorder data generation center for Single Cell Opioid Responses in the Context of HIV
M-SCORCH:艾滋病毒背景下单细胞阿片类药物反应的甲基苯丙胺使用障碍数据生成中心
- 批准号:
10404681 - 财政年份:2021
- 资助金额:
$ 85.69万 - 项目类别:
M-SCORCH: Methamphetamine use disorder data generation center for Single Cell Opioid Responses in the Context of HIV
M-SCORCH:艾滋病毒背景下单细胞阿片类药物反应的甲基苯丙胺使用障碍数据生成中心
- 批准号:
10220577 - 财政年份:2021
- 资助金额:
$ 85.69万 - 项目类别:
M-SCORCH: Methamphetamine use disorder data generation center for Single Cell Opioid Responses in the Context of HIV
M-SCORCH:艾滋病毒背景下单细胞阿片类药物反应的甲基苯丙胺使用障碍数据生成中心
- 批准号:
10588171 - 财政年份:2021
- 资助金额:
$ 85.69万 - 项目类别:
Role of clonal expansion in HIV-1 persistence
克隆扩增在 HIV-1 持久性中的作用
- 批准号:
10222530 - 财政年份:2018
- 资助金额:
$ 85.69万 - 项目类别:
Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence for persons living with HIV and opioid use disorders
评估阿片类药物辅助疗法对艾滋病毒感染者和阿片类药物使用障碍患者的 HIV-1 持续存在的作用
- 批准号:
10416609 - 财政年份:2018
- 资助金额:
$ 85.69万 - 项目类别:
Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence for persons living with HIV and opioid use disorders
评估阿片类药物辅助疗法对艾滋病毒感染者和阿片类药物使用障碍患者的 HIV-1 持续存在的作用
- 批准号:
10458790 - 财政年份:2018
- 资助金额:
$ 85.69万 - 项目类别:
Role of clonal expansion in HIV-1 persistence
克隆扩增在 HIV-1 持久性中的作用
- 批准号:
10458573 - 财政年份:2018
- 资助金额:
$ 85.69万 - 项目类别:
Role of clonal expansion in HIV-1 persistence
克隆扩增在 HIV-1 持久性中的作用
- 批准号:
9766189 - 财政年份:2018
- 资助金额:
$ 85.69万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 85.69万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 85.69万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 85.69万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 85.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 85.69万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 85.69万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 85.69万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 85.69万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 85.69万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 85.69万 - 项目类别:














{{item.name}}会员




